Biopharmx Corporatio (BPMX) 3.0000 $BPMX
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
PR Newswire - Wed Dec 10, 8:00AM CST
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
BioPharmX unveils Violet iodine for relief of premenstrual breast discomfort and symptoms associated with Fibrocystic Breast Condition
M2 - Wed Dec 10, 6:27AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Tuesday the market launch of its new, once-daily pill for relief of premenstrual breast discomfort, Violet iodine.
WAG: 76.67 (+0.16)
Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
PR Newswire - Tue Dec 09, 8:37AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
WAG: 76.67 (+0.16)
BioPharmX Corporation Announces Submission Of Pre-IND Meeting Request To The U.S. FDA For Its Topical Acne Solution
PR Newswire - Tue Dec 02, 6:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's topical antibiotic acne compound currently under development. The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company's proposed strategy and plan for conducting safety and toxicology studies and human clinical trials required for approval of its acne product.
BiopharmX Announces Breast Health Medical Advisory Board
PR Newswire - Mon Nov 17, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the formation of a Breast Health Medical Advisory Board (MAB) composed of highly respected physicians selected to provide a depth and range of experience in breast health. Members will serve as a strategic resource to BioPharmX as it develops products that address unmet breast health needs. Specifically, the advisory board will provide clinical trial and protocol design advice and guidance regarding emerging breast health trends and new product opportunities.
BioPharmX Corporation Announces Appointment Of Ping Wang Of Korea Investment Partners To Board Of Directors
PR Newswire - Mon Nov 10, 7:10AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Mr. Ping Wang, Principal of Korea Investment Partners, to the company's board of directors. Mr. Wang's appointment follows Korea Investment Partners' investment in BioPharmX as part of its Series A private placement, which was also announced today.
BioPharmX Corporation Secures Up To $12 Million In Private Placement
PR Newswire - Mon Nov 10, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, announced that the Company has secured up to $12 million in a Series A private placement (Series A). The $12 million in total funding secured includes convertible notes previously converted to common shares, as well as the Series A private placement, which was completed in a series of closings that occurred between May 2014 and November 2014. The total amount includes $2 million in funding subject to the company achieving certain milestones. The proceeds are being used to advance the Company's pipeline of products in the fields of women's health and dermatology and to fund the near-term launch and commercialization of the Company's women's health product. The Series A private placement was led by Korea Investment Partners (KIP), which is now represented on BioPharmX's board of directors, and complemented by a combination of accredited institutional investors and high-net worth private individuals.
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
PR Newswire - Wed Dec 10, 8:00AM CST
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
BioPharmX unveils Violet iodine for relief of premenstrual breast discomfort and symptoms associated with Fibrocystic Breast Condition
M2 - Wed Dec 10, 6:27AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Tuesday the market launch of its new, once-daily pill for relief of premenstrual breast discomfort, Violet iodine.
WAG: 76.67 (+0.16)
Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
PR Newswire - Tue Dec 09, 8:37AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
WAG: 76.67 (+0.16)
BioPharmX Corporation Announces Submission Of Pre-IND Meeting Request To The U.S. FDA For Its Topical Acne Solution
PR Newswire - Tue Dec 02, 6:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's topical antibiotic acne compound currently under development. The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company's proposed strategy and plan for conducting safety and toxicology studies and human clinical trials required for approval of its acne product.
BiopharmX Announces Breast Health Medical Advisory Board
PR Newswire - Mon Nov 17, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the formation of a Breast Health Medical Advisory Board (MAB) composed of highly respected physicians selected to provide a depth and range of experience in breast health. Members will serve as a strategic resource to BioPharmX as it develops products that address unmet breast health needs. Specifically, the advisory board will provide clinical trial and protocol design advice and guidance regarding emerging breast health trends and new product opportunities.
BioPharmX Corporation Announces Appointment Of Ping Wang Of Korea Investment Partners To Board Of Directors
PR Newswire - Mon Nov 10, 7:10AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Mr. Ping Wang, Principal of Korea Investment Partners, to the company's board of directors. Mr. Wang's appointment follows Korea Investment Partners' investment in BioPharmX as part of its Series A private placement, which was also announced today.
BioPharmX Corporation Secures Up To $12 Million In Private Placement
PR Newswire - Mon Nov 10, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, announced that the Company has secured up to $12 million in a Series A private placement (Series A). The $12 million in total funding secured includes convertible notes previously converted to common shares, as well as the Series A private placement, which was completed in a series of closings that occurred between May 2014 and November 2014. The total amount includes $2 million in funding subject to the company achieving certain milestones. The proceeds are being used to advance the Company's pipeline of products in the fields of women's health and dermatology and to fund the near-term launch and commercialization of the Company's women's health product. The Series A private placement was led by Korea Investment Partners (KIP), which is now represented on BioPharmX's board of directors, and complemented by a combination of accredited institutional investors and high-net worth private individuals.
